source
- #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphomaTwo plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
- Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trialData presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…